Venus Medtech (Hangzhou) Past Earnings Performance
Past criteria checks 0/6
Venus Medtech (Hangzhou)'s earnings have been declining at an average annual rate of -42.6%, while the Medical Equipment industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 16.9% per year.
Key information
-42.6%
Earnings growth rate
-34.9%
EPS growth rate
Medical Equipment Industry Growth | 13.7% |
Revenue growth rate | 16.9% |
Return on equity | -37.6% |
Net Margin | -267.2% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Venus Medtech (Hangzhou) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 452 | -1,208 | 500 | 602 |
31 Mar 23 | 429 | -1,133 | 468 | 565 |
31 Dec 22 | 406 | -1,058 | 437 | 527 |
30 Sep 22 | 397 | -759 | 411 | 451 |
30 Jun 22 | 387 | -461 | 382 | 374 |
31 Mar 22 | 401 | -417 | 364 | 316 |
31 Dec 21 | 416 | -374 | 345 | 258 |
30 Sep 21 | 415 | -313 | 320 | 231 |
30 Jun 21 | 413 | -252 | 295 | 204 |
31 Mar 21 | 345 | -217 | 267 | 186 |
31 Dec 20 | 276 | -182 | 239 | 167 |
30 Sep 20 | 252 | -210 | 247 | 165 |
30 Jun 20 | 228 | -238 | 256 | 163 |
31 Mar 20 | 231 | -310 | 289 | 182 |
31 Dec 19 | 233 | -381 | 322 | 201 |
31 Dec 18 | 115 | -300 | 291 | 105 |
31 Dec 17 | 18 | -157 | 56 | 117 |
Quality Earnings: 2500 is currently unprofitable.
Growing Profit Margin: 2500 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2500 is unprofitable, and losses have increased over the past 5 years at a rate of 42.6% per year.
Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).
Return on Equity
High ROE: 2500 has a negative Return on Equity (-37.59%), as it is currently unprofitable.